Melanotan II: Mechanism, Uses, and Safety Considerations

Melanotan II is a synthetic peptide that activates melanocortin receptors throughout the body, producing skin darkening, increased sexual arousal and reduced appetite. It is not FDA approved for any use, and when people use it for cosmetic tanning, they take on real risks, including nausea, blood pressure changes and changes in moles, without proven benefit to skin health.

Patients ask me about Melanotan II more often than you might expect, usually after seeing it promoted as a "sunless tan." Here is what the science does and does not support.

What Is Melanotan II?

Melanotan II (MT-II) is a small, ring-shaped (cyclic) peptide modeled on alpha-melanocyte-stimulating hormone (α-MSH), the body's natural signal for pigment production. It was developed at the University of Arizona in the 1980s and 1990s, originally with the idea that a tan produced without UV exposure might help protect fair-skinned people from sun damage.

Early human studies showed that MT-II could produce visible tanning. Researchers also noticed an unexpected effect: spontaneous erections and increased sexual desire. That observation eventually led to a different drug, bremelanotide, which is now FDA approved for a specific sexual health indication.

How Melanotan II Works

The key to understanding Melanotan II's effects, and its side effects, is that it is non-selective. It activates several melanocortin receptors at once:

• MC1R (skin pigment cells): Stimulates melanocytes to produce more eumelanin, the darker pigment. This causes tanning and darkening of freckles and moles.
• MC3R and MC4R (brain): Influence sexual arousal, appetite and energy balance. This explains increased libido, erections in men, and reduced appetite.
• MC5R and others: Involved in gland secretion and other functions that are less well understood.

Approved Relatives: Bremelanotide and Afamelanotide

Two related peptides show what careful drug development looks like:

• Bremelanotide (Vyleesi, PT-141) was derived from MT-II research and is FDA approved for premenopausal women with hypoactive sexual desire disorder. It went through controlled trials, has defined labeling, and has known side effects such as nausea and temporary blood pressure increases. You can read more in PT-141: the FDA-approved sexual health peptide.
• Afamelanotide (Scenesse), a melanocortin analog that acts mainly on pigment cells, was FDA approved in 2019 as an implant to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare genetic light-sensitivity disorder.

Neither approval extends to Melanotan II, and neither is a cosmetic tanning product.

Known Side Effects of Melanotan II

What we know about Melanotan II's side effects comes from small early clinical studies, case reports and user experience, not from large safety trials. Commonly described effects include:

• Nausea and sometimes vomiting, especially with early doses
• Facial flushing
• Reduced appetite
• Spontaneous erections in men and increased libido
• Darkening of existing moles and freckles, and the appearance of new dark spots
• Fatigue and headache

Less common but more serious problems have been described in published case reports, including prolonged erections (priapism), significant blood pressure changes, and rapidly changing or atypical moles. Case reports cannot prove cause and effect, but they are the kind of warning signal that deserves respect when the benefit is purely cosmetic.

The skin cancer question

The concern most dermatologists raise is melanoma. Melanotan II stimulates the very cells that give rise to melanoma, and it makes moles darker, which can make it harder to spot a dangerous change. Whether it directly increases melanoma risk has not been established, because no adequate long-term studies exist. Many users also combine it with sunbathing or tanning beds, which do raise skin cancer risk. A darker tan does not equal full UV protection.

Melanotan II and FDA Status

• Melanotan II is not FDA approved for any indication.
• In 2023, FDA placed it in "Category 2" of its 503A bulk-substance list, signaling safety concerns for compounding.
• On April 15, 2026, FDA removed it, along with 11 other peptides, from Category 2 so its Pharmacy Compounding Advisory Committee could review it. That review is expected before February 2027.

Removal from Category 2 for review is not approval and not permission to compound. As of this writing, check current FDA guidance. Health regulators in several other countries have also issued public warnings about unlicensed tanning injections. Most Melanotan II in circulation is sold online as a "research chemical," with unverified identity, purity and sterility. For more on why that matters, see why self-injecting research peptides can be risky.

Safer Ways to Address What People Want From It

When I talk with patients interested in Melanotan II, the underlying goal is usually one of three things:

• A tan: Sunless tanning lotions and sprays (dihydroxyacetone) color the outer skin layer without systemic effects.
• Sun protection: Broad-spectrum sunscreen, protective clothing and regular skin checks remain the evidence-based approach.
• Libido or sexual function: These deserve a medical evaluation, including hormones, medications, mood and cardiovascular health. FDA-approved options exist for specific situations.

At Laeeq M.D., I review the full picture before discussing any peptide, and I am direct when a compound's risks outweigh its benefits. The Melanotan II evidence summary in our peptide library goes into more detail.

Sources

• Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization — Peptides, 2006. https://pubmed.ncbi.nlm.nih.gov/16412534/
• FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder — U.S. Food and Drug Administration news release (via BioSpace), 2019. https://www.biospace.com/fda-approves-first-treatment-to-increase-pain-free-light-exposure-in-patients-with-a-rare-disorder
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Book a Consultation

If you are considering Melanotan II or want an honest discussion of skin, libido or appetite concerns, start with a medical evaluation. You can book a consultation for a 60-minute visit with Dr. Laeeq, virtually or in person in Reston, VA.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.